Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 11NIH 2UNKNOWN 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leiomyosarcoma 1

Interventions

Radiotherapy, Intensity-Modulated 3Radiotherapy 2Epirubicin 2Cytarabine 2pirarubicin 1durvalumab 1aclacinomycins 1Temozolomide 1Sorafenib 1Radiotherapy, Adjuvant 1Radiation Dose Hypofractionation 1Povidone-Iodine 1Pleurodesis 1Paclitaxel 1Nutrition Assessment 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Methylene Blue 1Indocyanine Green 1Equipment and Supplies 1Drug Therapy 1Doxorubicin 1Docetaxel 1Daunorubicin 1Cyclophosphamide 1Cabergoline 1CAG protocol 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × UNKNOWN × Temozolomide × Clear all
NCT05204524 2022-01-24

Temozolomide for Injection Combined With Epirubicin in First-line Treatment of Leiomyosarcoma

ChineseAMS

Phase NA Unknown
28 enrolled
Sarcoma

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡